Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7411 to 7425 of 7707 results

  1. Inhaler devices for routine treatment of chronic asthma in older children (aged 5 to 15 years) (TA38)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Technology appraisal guidance
    Published
    27 March 2002

  2. Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over (TA138)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Technology appraisal guidance
    Published
    26 March 2008

  3. Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Technology appraisal guidance
    Published
    28 November 2007

  4. Non-invasive skin closure devices for surgical incisions (MT775)

    In development [GID-MT593] Expected publication date: TBC

    Medical technologies guidance
    In development

  5. Stye: antimicrobial prescribing

    Discontinued [GID-NG10167]

    Antimicrobial prescribing guideline
    Discontinued

  6. Skin abscess: antimicrobial prescribing

    Discontinued [GID-NG10163]

    Antimicrobial prescribing guideline
    Discontinued

  7. SILK artery reconstruction device (discontinued)

    Discontinued [GID-MT81]

    Medical technologies guidance
    Discontinued

  8. Housing: planning to improve health and wellbeing

    Discontinued [GID-NG10053]

    NICE guideline
    Discontinued

  9. Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

    In development [GID-TA10607] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

    Discontinued [GID-TAG363]

    Technology appraisal guidance
    Discontinued

  11. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued [GID-TAG387]

    Technology appraisal guidance
    Discontinued

  12. Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) [ID622]

    Discontinued [GID-TAG360]

    Technology appraisal guidance
    Discontinued

  13. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued [GID-TAG403]

    Technology appraisal guidance
    Discontinued

  14. Prostate cancer (prevention) - dutasteride [ID75]

    Discontinued [GID-TAG409]

    Technology appraisal guidance
    Discontinued

  15. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued [GID-TAG383]

    Technology appraisal guidance
    Discontinued